Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders

Journal of Gastroenterology

Volumn 45, Issue 11, 2010, Pages 1163-1171

  Kaneko, Yoshibumi ^a   Miyajima, Hiroaki ^b   Piperno, Alberto ^c   Tomosugi, Naohisa ^d   Hayashi, Hisao ^e   Morotomi, Natsuko ^f   Tsuchida, Ken Ichi ^g   Ikeda, Takaaki ^h   Ishikawa, Akihisa ⁱ   Ota, Yusuke ^j   Wakusawa, Shinya ^k   Yoshioka, Kentaro ^k   Kono, Satoshi ^b   Pelucchi, Sara ^c   Hattori, Ai ^e   Tatsumi, Yasuaki ^e   Okada, Toshihide ^a   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e AICHI GAKUIN UNIVERSITY   (Japan)

^f Japanese Seamen's Relief Association   (Japan)

^g Manda Memorial Hospital   (Japan)

^h YOKOSUKA KYOSAI HOSPITAL   (Japan)

ⁱ Hitachi   (Japan)

^j Department of Internal Medicine   (Japan)

^k FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Ceruloplasmin; Hemochromatosis; Hepcidin

Indexed keywords

CELL PROTEIN; CERULOPLASMIN; FERROPORTIN; HEPCIDIN; HEPCIDIN 25; HFE PROTEIN; IRON; PROTEIN HAMP; PROTEIN HJV; PROTEIN SLC40A1; PROTEIN TFR2; UNCLASSIFIED DRUG;

ACERULOPLASMINEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FERROPORTIN DISEASE; GENE; GENOTYPE; HAMP GENE; HEMOCHROMATOSIS; HFE GENE; HJV GENE; HJV HEMOCHROMATOSIS; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPERFERRITINEMIA; IRON BLOOD LEVEL; IRON OVERLOAD; JAPANESE; LIQUID CHROMATOGRAPHY; MALE; METABOLIC DISORDER; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SLC40A1 GENE; TANDEM MASS SPECTROMETRY; TFR2 GENE; TFR2 HEMOCHROMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CERULOPLASMIN; CHROMATOGRAPHY, LIQUID; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HUMANS; IRON METABOLISM DISORDERS; IRON OVERLOAD; JAPAN; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; RECEPTORS, TRANSFERRIN; TANDEM MASS SPECTROMETRY;

EID: 78651265056     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0259-8     Document Type: Article

References (50)

1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
2. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dubé MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
3. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al. Mutant antimicrobial hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21-22.
4. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14-15.
5. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147-150.
6. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806-7810.
7. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780-8785.
8. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811-7819.
9. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
10. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461-2463.
11. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108:3730-3735.
12. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFEassociated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet. 2003;361:669-673.
13. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, et al. Hepcidin in iron overload disorders. Blood. 2005;105:4103-4105.
14. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105:1803-1806.
15. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepacidin secretion. J Hepatol. 2008;49:702-710.
16. van Dijk BA, Laarakkers CM, Klaver SM, Jacobs EM, van Tits LJ, Janssen MC, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Yhomozygotes with elevated and normal ferritin levels. Br J Haematol. 2008;142(6):979-985.
17. Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51:845-852.
18. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology. 1987;37:761-767.
19. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RTA, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A. 1995;92:2539-2543.
20. de Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmine. EMBO J. 2007;26:2823-2831.
21. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001;28:213-214.
22. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Investig. 2001;108:619-623.
23. Jouanolle AM, Douabin-Gicquel V, Halimi C, Loreal O, Fergelot P, Delacour T, et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol. 2003;39:286-9.
24. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis. 2003;31:305-9.
25. Koyama C, Wakusawa S, Hayashi H, Ueno T, Suzuki R, Yano M, et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med. 2005;44:990-3.
26. Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica. 2003;88:824-6.
27. Zoller H, McFarlane I, Theurl I, Stadlmann S, Nemeth E, Oxley D, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology. 2005;42:2-466.
28. Cemonesi L, Forni GL, Soriani N, Lamagna M, Fermo I, Daraio F, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol. 2005;131:663-70.
29. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1(Suppl 1):S9-18.
30. Bonkovsky H, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-68.
31. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol. 2007;13:4699-707.
32. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem. 2002;277:37597-603.
33. Koyama C, Wakusawa S, Hayashi H, Suzuki R, Yano M, Yoshioka K, et al. Two novel mutations, L490R and V561X, in the transferrin receptor 2 in Japanese patients with hemochromatosis. Haematologica. 2005;90:302-7.
34. Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol. 2005;43:740-2.
35. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid cleanup. Rapid Commun Mass Spectrom. 2007;21:4033-8.
36. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood. 2007;110:1048-54.
37. Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica. 2008;93:1550-4.
38. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275-8.
39. Lok CY, Merryweather-Clarke AT, Viprakasit V, Chinthammitr Y, Srichairatanakool S, Limwongse C, et al. Iron overload in the Asian community. Blood. 2009;114(1):20-5.
40. Guo P, Cui R, Chang YZ, Wu WS, Qian ZM. Hepcidin, an antimicrobial peptide is down regulated in ceruloplasmin-deficient mice. Peptides. 2009;30:262-6.
41. Johnson MB, Enns CA. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood. 2004;104:4287-93.
42. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood. 2004;104:4294-9.
43. De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A. 2005;102(25):8955-60.
44. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005;106(3):1092-7. (Pubitemid 41076459)
45. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosisassociated FPN mutations. Blood. 2005;105(10):4096-102.
46. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepatic mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol. 2005;39:71-4.
47. Lin TJ, Liao LY, Chou JM, Liu SO, Wang CK. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients. Hepatogastroenterology. 2009;56:1146-51.
48. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292-7.
49. Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, et al. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut. 2004;53:756-8.
50. Hattori A, Wakusawa S, Hayashi H, Harashima A, Sanae F, Kawanaka M, et al. AVAQ 594-597 deletion of the TFR2 gene in a Japanese family with hemochromatosis. Hepatol Res. 2003;26:154-5.